Enkephalin release promotes homeostatic increases in constitutively active mu opioid receptors during morphine withdrawal

Neuroscience

Volumn 149, Issue 3, 2007, Pages 642-649

  Shoblock, J R ^a   Maidment, N T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

conditioned place aversion; dependence; inverse agonist; knockout mice; naloxone; opiate addiction

Indexed keywords

6 ALPHA NALOXOL; 6 BETA NALOXOL; ENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONDITIONING; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; HABITUATION; HOMEOSTASIS; JUMPING; KNOCKOUT MOUSE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OPIATE ADDICTION; PLACE PREFERENCE; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; ENKEPHALINS; HOMEOSTASIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; PROTEIN PRECURSORS; RECEPTORS, OPIOID, MU; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 35448972963     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.05.011     Document Type: Article

References (47)

1. Azar M.R., Jones B.C., and Schulteis G. Conditioned place aversion is a highly sensitive index of acute opioid dependence and withdrawal. Psychopharmacology (Berl) 170 (2003) 42-50
2. Bals-Kubik R., Herz A., and Shippenberg T.S. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology 98 (1989) 203-206
3. Bilsky E.J., Bernstein R.N., Wang Z., Sadee W., and Porreca F. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 277 (1996) 484-490
4. Blokhina E.A., Sukhotina I.A., and Bespalov A.Y. Pretreatment with morphine potentiates naloxone-conditioned place aversion in mice: effects of NMDA receptor antagonists. Eur J Pharmacol 406 (2000) 227-232
5. Burford N.T., Wang D., and Sadee W. G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity. Biochem J 348 Pt 3 (2000) 531-537
6. Chatterjie N., and Inturrisi C.E. Stereospecific synthesis of the 6beta-hydroxy metabolites of naltrexone and naloxone. J Med Chem 18 (1975) 490-492
7. Cruz S.L., Villarreal J.E., and Volkow N.D. Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal. Life Sci 58 (1996) L381-L389
8. De Vries T.J., Babovic-Vuksanovic D., Elmer G., and Shippenberg T.S. Lack of involvement of delta-opioid receptors in mediating the rewarding effects of cocaine. Psychopharmacology (Berl) 120 (1995) 442-448
9. Evans C.J., Erdelyi E., and Barchas J.D. Candidate opioid peptides for interaction with the immune system. In: Plotnikoff N.P., Faith R.E., Murgo A.J., and Good R.A. (Eds). Enkephalins and endorphins: stress and the immune system (1986), Plenum Press, New York 3-15
10. Freye E., and Levy J. Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal. Addict Biol 10 (2005) 131-137
11. Fukunaga Y., and Kishioka S. Enkephalinergic neurons in the periaqueductal gray and morphine withdrawal. Jpn J Pharmacol 82 (2000) 175-180
12. Fukunaga Y., Nishida S., Inoue N., Kishioka S., and Yamamoto H. Increase of preproenkephalin mRNA in the caudal part of periaqueductal gray by morphine withdrawal in rats: a quantitative in situ hybridization study. Brain Res Mol Brain Res 42 (1996) 128-130
13. Fukunaga Y., Nishida S., Inoue N., Miyamoto M., Kishioka S., and Yamamoto H. Time course of morphine withdrawal and preproenkephalin gene expression in the periaqueductal gray of rats. Brain Res Mol Brain Res 55 (1998) 221-231
14. Gracy K.N., Dankiewicz L.A., and Koob G.F. Opiate withdrawal-induced fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology 24 (2001) 152-160
15. Gudehithlu K.P., and Bhargava H.N. Modulation of preproenkephalin mRNA levels in brain regions and spinal cord of rats treated chronically with morphine. Peptides 16 (1995) 415-419
16. Heinzen E.L., Booth R.G., and Pollack G.M. Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the mu-opioid receptor. Biochem Pharmacol 69 (2005) 679-688
17. Hunyady L., Vauquelin G., and Vanderheyden P. Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends Pharmacol Sci 24 (2003) 81-86
18. Koman A., Einarsson M., and Terenius L. Agonist-antagonist properties of fluorescent opioid probes in the guinea-pig myenteric plexus-longitudinal muscle preparation. Naunyn Schmiedebergs Arch Pharmacol 331 (1985) 355-358
19. Konig M., Zimmer A.M., Steiner H., Holmes P.V., Crawley J.N., Brownstein M.J., and Zimmer A. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383 (1996) 535-538
20. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 (2001) 52-58
21. Kreek M.J., and Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51 (1998) 23-47
22. Liu J.G., and Prather P.L. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol 60 (2001) 53-62
23. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., and Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383 (1996) 819-823
24. Mucha R.F., and Walker M.J. Aversive property of opioid receptor blockade in drug-naive mice. Psychopharmacology (Berl) 93 (1987) 483-488
25. Neilan C.L., Akil H., Woods J.H., and Traynor J.R. Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists. Br J Pharmacol 128 (1999) 556-562
26. Nieto M.M., Wilson J., Cupo A., Roques B.P., and Noble F. Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: a microdialysis study. J Neurosci 22 (2002) 1034-1041
27. Nitsche J.F., Schuller A.G., King M.A., Zengh M., Pasternak G.W., and Pintar J.E. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J. Neurosci 22 (2002) 10906-10913
28. Nylander I., Vlaskovska M., and Terenius L. The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology (Berl) 118 (1995) 391-400
29. Olive M.F., Bertolucci M., Evans C.J., and Maidment N.T. Microdialysis reveals a morphine-induced increase in pallidal opioid peptide release. Neuroreport 6 (1995) 1093-1096
30. Parker L.A., Cyr J.A., Santi A.N., and Burton P.D. The aversive properties of acute morphine dependence persist 48 h after a single exposure to morphine. Evaluation by taste and place conditioning. Pharmacol Biochem Behav 72 (2002) 87-92
31. Parker L.A., and Joshi A. Naloxone-precipitated morphine withdrawal induced place aversions: effect of naloxone at 24 hours postmorphine. Pharmacol Biochem Behav 61 (1998) 331-333
32. Pierce T.L., Tiong G.K., and Olley J.E. Morphine and methadone dependence in the rat: withdrawal and brain met-enkephalin levels. Pharmacol Biochem Behav 42 (1992) 91-96
33. Raehal K.M., Lowery J.J., Bhamidipati C.M., Paolino R.M., Blair J.R., Wang D., Sadee W., and Bilsky E.J. In vivo characterization of 6{beta}-naltrexol, an opioid ligand with less inverse agonist activity compared to naltrexone and naloxone in opioid dependent mice. J Pharmacol Exp Ther 313 (2005) 1150-1162
34. Ronai A.Z., Foldes F.F., Hahn E.F., and Fishman J. Orientation of the oxygen atom at C-6 as a determinant of agonistic activity in the oxymorphone series. J Pharmacol Exp Ther 200 (1977) 496-500
35. Schulteis G., Markou A., Gold L.H., Stinus L., and Koob G.F. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J Pharmacol Exp Ther 271 (1994) 1391-1398
36. Seifert R., and Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366 (2002) 381-416
37. Selley D.E., Cao C.C., Liu Q., and Childers S.R. Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus. Br J Pharmacol 130 (2000) 987-996
38. Shippenberg T.S., Bals-Kubik R., and Herz A. Motivational properties of opioids: evidence that an activation of delta-receptors mediates reinforcement processes. Brain Res 436 (1987) 234-239
39. Shoblock J.R., and Maidment N.T. Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice. Neuropsychopharmacology 31 (2006) 171-177
40. Skoubis P.D., Lam H.A., Shoblock J., Narayanan S., and Maidment N.T. Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice. Eur J Neurosci 21 (2005) 1379-1384
41. Skoubis P.D., Matthes H.W., Walwyn W.M., Kieffer B.L., and Maidment N.T. Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice. Neuroscience 106 (2001) 757-763
42. Walker E.A., and Sterious S.N. Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence. Br J Pharmacol 145 (2005) 975-983
43. Wang D., Raehal K.M., Bilsky E.J., and Sadee W. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J. Neurochem 77 (2001) 1590-1600
44. Wang D., Raehal K.M., Lin E.T., Lowery J.J., Kieffer B.L., Bilsky E.J., and Sadee W. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 308 (2004) 512-520
45. Wang Z., Arden J., and Sadee W. Basal phosphorylation of mu opioid receptor is agonist modulated and Ca2+-dependent. FEBS Lett 387 (1996) 53-57
46. Wang Z., Bilsky E.J., Porreca F., and Sadee W. Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54 (1994) L339-L350
47. Wang Z., Bilsky E.J., Wang D., Porreca F., and Sadee W. 3-Isobutyl-1-methylxanthine inhibits basal mu-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice. Eur J Pharmacol 371 (1999) 1-9